WO2021124847A1

WO2021124847A1 - Blood collection container

Info

Publication number: WO2021124847A1
Application number: PCT/JP2020/044441
Authority: WO
Inventors: 瀬戸口　雄二; 五十川　浩信
Original assignee: 積水メディカル株式会社; 徳山積水工業株式会社
Priority date: 2019-12-18
Filing date: 2020-11-30
Publication date: 2021-06-24

Abstract

Provided is a blood collection container with which it is possible to inhibit, when blood containing heparin is made to coagulate, the occurrence of blood clot in which air bubbles are trapped, to inhibit, when blood containing heparin is separated into serum and blood clot, the product of fibrin in the separated serum.　The blood collection container according to the present invention is provided with a blood collection container body having an opening at one end and a closed bottom section at the other end, serine protease positioned in the blood collection container body, and a heparin neutralizer positioned in the blood collection container body. When the region in which the serine protease is positioned is deemed to be a first region and the region in which the heparin neutralizer is deemed to be a second region, the second region is located farther in the other-end side than the other-end-side end part of the first region.

Description

Blood collection container

The present invention relates to a blood collection container.

In clinical examinations, blood collection containers such as blood collection tubes are widely used to collect blood samples. Blood can be separated into serum and blood clot by collecting blood in a blood collection container containing a serum separation composition, coagulating the blood, and then centrifuging the blood. At this time, the serum is located above the serum separation composition, and the blood clot is located below.

As an example of the blood collection container, the following Patent Document 1 contains a blood coagulation promoter and a defoaming agent which is a polyoxyalkylene or a derivative thereof, and the amount of the defoaming agent is the amount of blood collection. A blood collection container is disclosed in which the amount of blood collected in the container is ^{2.0 × 10 -3} mg to 0.2 mg per 1 mL of blood.

Further, Patent Document 2 below discloses a blood test container in which a blood coagulation promoter is present inside a bottomed tubular container. The blood coagulation promoter contains thrombin or thrombin-like serine protease as a blood coagulation promoting component, contains an organic compound having an amine salt and / or quaternary nitrogen as a heparin neutralizing component, and serves as a blood clot stabilizing component. Contains anti-serine solvents or anti-plasmin agents. Patent Document 2 describes that even blood containing heparin can be coagulated in a short time by using the above-mentioned blood test container.

WO2010 / 024325A1 Japanese Unexamined Patent Publication No. 8-154697

The blood of heparin-administered patients such as dialysis patients or thrombosis patients is less likely to coagulate than normal blood. Therefore, when trying to separate heparin-containing blood into serum and blood clot using a conventional blood collection container as described in Patent Document 1, coagulation cannot be performed in a short time, or the blood may not be coagulated with serum. It may not be able to separate well from the blood clot.

On the other hand, Patent Document 2 describes a blood collection container in which a heparin neutralizer and a blood coagulation promoting component (serine protease such as thrombin) are arranged at the same position. By using a blood collection container in which a heparin neutralizer is arranged, blood containing heparin can be coagulated in a short time, and blood containing heparin can be separated into serum and blood clot to some extent well. ..

However, in the blood collection container described in Patent Document 2, when blood containing heparin is coagulated, a blood clot (so-called foam-biting fibrin) in which bubbles are caught may be generated. When a blood clot in which bubbles are caught is generated, the blood clot floats on the serum side during centrifugation, and red blood cells or the like may be mixed in the serum, which may affect the serum test result.

Further, in the blood collection container described in Patent Document 2, when blood containing heparin is separated into serum and blood clot using a serum separation composition, fibrin may be produced in the separated serum. The production of fibrin (so-called delayed fibrin) in the serum after separation is due to poor coagulation, which can also affect serum test results.

An object of the present invention is that when blood containing heparin is coagulated, the generation of blood clots in which bubbles are caught can be suppressed, and when blood containing heparin is separated into serum and blood clots, It is to provide a blood collection vessel capable of suppressing the production of fibrin in the serum after separation.

According to a broad aspect of the present invention, a blood collection vessel body having an opening at one end and a closed bottom at the other end, a serine protease disposed within the blood collection container body, and the blood collection container. When the heparin neutralizing agent arranged in the main body is provided, the region where the serine protease is arranged is defined as the first region, and the region where the heparin neutralizing agent is arranged is defined as the second region, the above. A blood collection vessel is provided in which the second region has a region located on the other end side of the first region on the other end side of the other end side.

In a specific aspect of the blood collection vessel according to the present invention, there is no or exists an overlapping region where the first region and the second region overlap, and the first region and the second region When there is an overlapping region in which the first region and the second region overlap with respect to the distance between the end portion on the one end side and the end portion on the other end side of the second region, the first region and the second region overlap. The ratio of the distance between the end on one end side of the region and the end on the other end side is 0.2 or less.

In another specific aspect of the blood collection container according to the present invention, the blood collection container includes an inorganic powder arranged in the blood collection container main body, and a region in which the inorganic powder is arranged is referred to as a third region. The third region has a region existing on the other end side of the other end side of the first region.

In yet another specific aspect of the blood collection vessel according to the present invention, the third region has a region existing on one end side of the second region on one end side.

In yet another specific aspect of the blood collection vessel according to the present invention, the second region has a region existing on the other end side of the other end side of the third region.

In yet another specific aspect of the blood collection vessel according to the present invention, the inorganic powder is silica powder.

In yet another particular aspect of the blood collection vessel according to the present invention, the serine protease is thrombin, a thrombin-like enzyme, or a fibrinogen-degrading enzyme.

In yet another specific aspect of the blood collection container according to the present invention, the blood collection container includes a defoaming agent arranged at least at the bottom of the blood collection container body.

In yet another particular aspect of the blood collection vessel according to the present invention, the blood collection container comprises a serum separation composition housed in the bottom of the blood collection container body.

The blood collection container according to the present invention has a blood collection container main body having an opening at one end and a closed bottom at the other end, a serine protease arranged in the blood collection container main body, and the blood collection container. It is equipped with a heparin neutralizer placed in the main body. In the present invention, the region where the serine protease is arranged is defined as the first region, and the region where the heparin neutralizer is arranged is defined as the second region. In the blood collection container according to the present invention, the second region has a region existing on the other end side of the other end side of the first region. Since the blood collection container according to the present invention has the above configuration, it is possible to suppress the generation of blood clots in which bubbles are caught when coagulating blood containing heparin, and it also contains heparin. When blood is separated into serum and blood clot, the production of fibrin in the separated serum can be suppressed.

FIG. 1 is a front sectional view of a blood collection container according to the first embodiment of the present invention. FIG. 2 is a front sectional view of the blood collection container according to the second embodiment of the present invention. FIG. 3 is a front sectional view of the blood collection container according to the third embodiment of the present invention. FIG. 4 is a front sectional view of the blood collection container according to the fourth embodiment of the present invention. FIG. 5 is a front sectional view of the blood collection container according to the fifth embodiment of the present invention. FIG. 6 is a front sectional view of the blood collection container according to the sixth embodiment of the present invention. FIG. 7 is a front sectional view of the blood collection container according to the seventh embodiment of the present invention.

Hereinafter, the present invention will be described in detail.

The blood collection container according to the present invention has a blood collection container main body having an opening at one end and a closed bottom at the other end, a serine protease arranged in the blood collection container main body, and the blood collection container. It is equipped with a heparin neutralizer placed in the main body.

In the present invention, the region where the serine protease is arranged is defined as the first region, and the region where the heparin neutralizer is arranged is defined as the second region. In the blood collection container according to the present invention, the second region has a region existing on the other end side of the other end side of the first region.

Since the blood collection container according to the present invention has the above configuration, it is possible to suppress the generation of blood clots in which bubbles are caught when coagulating blood containing heparin, and it also contains heparin. When blood is separated into serum and blood clot, the production of fibrin in the separated serum can be suppressed. Further, in the blood collection container according to the present invention, blood containing heparin can be coagulated in a short time. In the blood collection container according to the present invention, for example, blood containing 1 unit of heparin can be coagulated in 5 to 10 minutes.

In a conventional blood collection container containing a heparin neutralizer, a heparin neutralizer and a blood coagulation promoting component (serine protease such as thrombin) are applied to the entire inner surface of the blood collection container body. When blood containing heparin is collected in this blood collection container, the present inventors proceed with a blood coagulation reaction at the same time as blood collection, and a blood clot in which bubbles such as bubbles generated at the time of blood collection are caught is generated. It was also found that fibrin is produced in the serum after separation due to poor coagulation.

Furthermore, the present inventors put heparin in a blood collection container in which a mixture of a heparin neutralizing agent and a blood coagulation promoting component (serine protease such as thrombin) is arranged in a narrow range near the opening of the blood collection container body. It was found that the following are likely to occur when blood containing blood is collected. That is, when the present inventors collect blood containing heparin in this blood collection container, the heparin-antithrombin III complex contained in the blood dramatically promotes the inactivation reaction of thrombin, and the bubbles bite. It was found that the development of thrombin clots and the production of fibrin in the serum after separation are more likely to occur.

On the other hand, in the blood collection container according to the present invention, the region where the heparin neutralizer is arranged (second region) is lower than the region where the serine protease is arranged (first region). It has a portion arranged on the side (the other end side of the blood collection container body). Therefore, when blood containing heparin is collected using the blood collection container according to the present invention, the blood comes into contact with the heparin neutralizer before the serine protease, so that the heparin neutralizer contains heparin in the blood. In harmony, the formation of the heparin-antithrombin III complex can be effectively suppressed. Then, by inversion mixing or the like, the blood and the serine protease come into contact with each other, the blood coagulation reaction proceeds effectively, and the blood can be coagulated in a short time. Further, when the inorganic powder is arranged in the blood collection container body, the blood coagulation reaction can proceed more effectively. Therefore, it is possible to suppress the generation of blood clots in which bubbles are bitten and the production of fibrin in the serum after separation.

Hereinafter, specific embodiments of the present invention will be described with reference to the drawings.

FIG. 1 is a front sectional view of a blood collection container according to the first embodiment of the present invention.

The blood collection container 11 includes serine protease 1 (layer containing serine protease), heparin neutralizer 2 (layer containing heparin neutralizer), inorganic powder 3 (layer containing inorganic powder), and a blood collection container main body. 4, a composition for separating serum 5, and a plug 6 are provided. The blood collection container body 4 has an opening at one end 4a and a bottom closed at the other end 4b. The serum separation composition 5 is housed in the bottom of the blood collection container body 4. The plug 6 is inserted into the opening of the blood collection container main body 4. Further, the blood collection container 11 includes an antifoaming agent (not shown) arranged at least at the bottom of the blood collection container main body 4. The blood collection container 11 is a vacuum blood collection tube.

The serine protease 1, the heparin neutralizing agent 2, the inorganic powder 3, and the defoaming agent are each arranged in the blood collection container main body 4 and adhere to the inner wall surface of the blood collection container main body 4, and are attached to the inner wall surface of the blood collection container main body 4. It is arranged on the inner wall surface of the main body 4.

The first region R1 is a region in which serine protease 1 is arranged. The first region R1 is an annular region.

The second region R2 is a region in which the heparin neutralizer 2 is arranged. The second region R2 is an annular region.

The third region R3 is a region in which the inorganic powder 3 is arranged. The third region R3 is an annular region.

In the blood collection container 11, the second region R2 has a region existing on the other end 4b side of the other end 4b side of the first region R1. In the blood collection container 11, the entire second region R2 exists on the other end 4b side of the other end 4b side of the first region R1. The end portion 2a on the one end 4a side of the second region R2 is located on the other end 4b side of the end portion 1b on the other end 4b side of the first region R1.

Therefore, in the blood collection container 11, there is no overlapping region where the first region R1 and the second region R2 overlap.

In the blood collection container 11, the third region R3 has a region existing on the other end 4b side of the other end 4b side of the first region R1. The end portion 3b on the other end 4b side of the third region R3 is located on the other end 4b side of the end portion 1b on the other end 4b side of the first region R1.

In the blood collection container 11, the first region R1 has a region existing on one end 4a side of the end portion 3a on the one end 4a side of the third region R3. The end portion 1a on the one end 4a side of the first region R1 is located on the one end 4a side of the end portion 3a on the one end 4a side of the third region R3. The end portion of the first region R1 on one end side and the end portion of the third region R3 on one end side may exist up to the vicinity of one end of the blood collection container main body, and may exist near one end of the blood collection container main body. In, it may be in the same position.

In the blood collection container 11, the end 1b on the other end 4b side of the first region R1 is located on the other end 4b side of the end 3a on the one end 4a side of the third region R3. Therefore, in the blood collection container 11, there is an overlapping region R13 in which the first region R1 and the third region R3 overlap. In the blood collection vessel 11, the overlapping region R13 is an annular region. In the blood collection vessel 11, the layer containing the serine protease is located inside the layer containing the inorganic powder in the overlapping region R13.

In the overlapping region R13, serine protease and inorganic powder coexist.

In the blood collection container 11, the third region R3 has a region existing on one end 4a side of the end portion 2a on the one end 4a side of the second region R2. The end portion 3a on the one end 4a side of the third region R3 is located on the one end 4a side of the end portion 2a on the one end 4a side of the second region R2.

In the blood collection container 11, the second region R2 has a region existing on the other end 4b side of the third region R3 on the other end 4b side end portion 3b. The end portion 2b on the other end 4b side of the second region R2 is located on the other end 4b side of the end portion 3b on the other end 4b side of the third region R3.

In the blood collection container 11, the end 2a on the one end 4a side of the second region R2 is located on the one end 4a side of the end 3b on the other end 4b side of the third region R3. Therefore, in the blood collection container 11, there is an overlapping region R23 in which the second region R2 and the third region R3 overlap. In the blood collection vessel 11, the overlapping region R23 is an annular region. In the blood collection vessel 11, the layer containing the heparin neutralizer is located inside the layer containing the inorganic powder in the overlapping region R23.

In the overlapping region R23, the heparin neutralizer and the inorganic powder coexist.

FIG. 2 is a front sectional view of the blood collection container according to the second embodiment of the present invention.

The blood collection container 11A includes serine protease 1A (layer containing serine protease), heparin neutralizer 2A (layer containing heparin neutralizer), inorganic powder 3A (layer containing inorganic powder), and a blood collection container main body. 4, a composition for separating serum 5, and a plug 6 are provided. The blood collection container body 4 has an opening at one end 4a and a bottom closed at the other end 4b. The serum separation composition 5 is housed in the bottom of the blood collection container body 4. The plug 6 is inserted into the opening of the blood collection container main body 4. Further, the blood collection container 11A includes an antifoaming agent (not shown) arranged at least at the bottom of the blood collection container main body 4. The blood collection container 11A is tubular and is a vacuum collection tube.

The serine protease 1A, the heparin neutralizer 2A, the inorganic powder 3A, and the antifoaming agent are each arranged in the blood collection container main body 4, and are attached to the inner wall surface of the blood collection container main body 4, respectively, and are attached to the inner wall surface of the blood collection container main body 4. It is arranged on the inner wall surface of No. 4.

The first region R1 is a region in which the serine protease 1A is arranged. The first region R1 is an annular region.

The second region R2 is a region in which the heparin neutralizer 2A is arranged. The second region R2 is an annular region.

The third region R3 is a region in which the inorganic powder 3A is arranged. The third region R3 is an annular region.

In the blood collection container 11A, the second region R2 has a region existing on the other end 4b side of the other end 4b side of the first region R1. The end portion 2Ab on the other end 4b side of the second region R2 is located on the other end 4b side of the end portion 1Ab on the other end 4b side of the first region R1.

In the blood collection container 11A, the first region R1 has a region existing on one end 4a side of the end portion 2Aa on the one end 4a side of the second region R2. The end portion 1Aa on the one end 4a side of the first region R1 is located on the one end 4a side of the end portion 2Aa on the one end 4a side of the second region R2.

In the blood collection container 11A, the end 1Ab on the other end 4b side of the first region R1 is located on the other end 4b side of the end 2Aa on the one end 4a side of the second region R2. Therefore, in the blood collection container 11A, there is an overlapping region R12 in which the first region R1 and the second region R2 overlap. In the blood collection vessel 11A, the overlapping region R12 is an annular region. In the blood collection vessel 11A, the layer containing the heparin neutralizer is located inside the layer containing the serine protease in the overlapping region R12.

In the overlapping region R12, serine protease and heparin neutralizer are mixed and present.

In the present invention, the overlapping region R12 in which the first region R1 and the second region R2 overlap is preferably extremely small, and more preferably no overlapping region exists. In this case, after the heparin in the blood is neutralized with a heparin neutralizer, the serine protease can be brought into contact with the blood to sufficiently coagulate the blood.

In the blood collection container 11A, the third region R3 has a region existing on the other end 4b side of the other end 4b side of the first region R1. In the blood collection container 11A, the entire third region R3 exists on the other end 4b side of the other end 4b side of the first region R1. The end portion 3Aa on the one end 4a side of the third region R3 is located on the other end 4b side of the end portion 1Ab on the other end 4b side of the first region R1.

Therefore, in the blood collection container 11A, there is no overlapping region where the first region R1 and the third region R3 overlap.

In the blood collection container 11A, the third region R3 has a region existing on the other end 4b side of the other end 4b side end portion 2Ab of the second region R2. The end portion 3Ab on the other end 4b side of the third region R3 is located on the other end 4b side of the end portion 2Ab on the other end 4b side of the second region R2.

In the blood collection container 11A, the second region R2 has a region existing on one end 4a side of the end portion 3Aa on the one end 4a side of the third region R3. The end portion 2Aa on the one end 4a side of the second region R2 is located on the one end 4a side of the end portion 3Aa on the one end 4a side of the third region R3.

In the blood collection container 11A, the end 2Ab on the other end 4b side of the second region R2 is located on the other end 4b side of the end 3Aa on the one end 4a side of the third region R3. Therefore, in the blood collection container 11A, there is an overlapping region R23 in which the second region R2 and the third region R3 overlap. In the blood collection vessel 11A, the overlapping region R23 is an annular region. In the blood collection vessel 11A, the layer containing the heparin neutralizer is located inside the layer containing the inorganic powder in the overlapping region R23.

FIG. 3 is a front sectional view of the blood collection container according to the third embodiment of the present invention.

The blood collection container 11B includes serine protease 1B (layer containing serine protease), heparin neutralizer 2B (layer containing heparin neutralizer), blood collection container body 4, serum separation composition 5, and stopper. It has a body 6. Unlike the blood collection container 11 shown in FIG. 1, the blood collection container 11B does not include an inorganic powder. The blood collection container body 4 has an opening at one end 4a and a bottom closed at the other end 4b. The serum separation composition 5 is housed in the bottom of the blood collection container body 4. The plug 6 is inserted into the opening of the blood collection container main body 4. Further, the blood collection container 11B includes an antifoaming agent (not shown) arranged at least at the bottom of the blood collection container main body 4. The blood collection container 11B is tubular and is a vacuum collection tube.

The serine protease 1B, the heparin neutralizer 2B, and the antifoaming agent are respectively arranged in the blood collection container main body 4 and adhere to the inner wall surface of the blood collection container main body 4, and are attached to the inner wall surface of the blood collection container main body 4. It is placed on top.

The first region R1 is a region in which serine protease 1B is arranged. The first region R1 is an annular region.

The second region R2 is a region in which the heparin neutralizer 2B is arranged. The second region R2 is an annular region.

In the blood collection container 11B, the second region R2 has a region existing on the other end 4b side of the other end 4b side of the first region R1. In the blood collection container 11B, the entire second region R2 exists on the other end 4b side of the other end 4b side of the first region R1. The end portion 2Ba on the one end 4a side of the second region R2 is located on the other end 4b side of the end portion 1Bb on the other end 4b side of the first region R1. Reference numeral 1Ba is an end portion of the first region R1 on the one end 4a side, and reference numeral 2Bb is an end portion of the second region R2 on the other end 4b side.

Therefore, in the blood collection container 11B, there is no overlapping region where the first region R1 and the second region R2 overlap. In the blood collection container not provided with the third region R3, unlike the blood collection container 11B shown in FIG. 3, even if there is an overlapping region R12 in which the first region R1 and the second region R2 overlap. It is good, but it is preferable that the overlapping region R12 is as small as possible.

FIG. 4 is a front sectional view of the blood collection container according to the fourth embodiment of the present invention.

The blood collection container 11C includes serine protease 1C (layer containing serine protease), heparin neutralizer 2C (layer containing heparin neutralizer), inorganic powder 3C (layer containing inorganic powder), and a blood collection container body. 4, a composition for separating serum 5, and a plug 6 are provided. The blood collection container body 4 has an opening at one end 4a and a bottom closed at the other end 4b. The serum separation composition 5 is housed in the bottom of the blood collection container body 4. The plug 6 is inserted into the opening of the blood collection container main body 4. Further, the blood collection container 11C includes an antifoaming agent (not shown) arranged at least at the bottom of the blood collection container main body 4. The blood collection container 11C is tubular and is a vacuum collection tube.

The serine protease 1C, the heparin neutralizer 2C, the inorganic powder 3C, and the defoaming agent are respectively arranged in the blood collection container main body 4 and adhere to the inner wall surface of the blood collection container main body 4, and the blood collection container main body 4 is attached. It is arranged on the inner wall surface of No. 4.

The first region R1 is a region in which serine protease 1C is arranged. The first region R1 is an annular region.

The second region R2 is a region in which the heparin neutralizer 2C is arranged. The second region R2 is an annular region.

The third region R3 is a region in which the inorganic powder 3C is arranged. The third region R3 is an annular region.

In the blood collection container 11C, the second region R2 has a region existing on the other end 4b side of the other end 4b side of the first region R1. In the blood collection container 11C, the entire second region R2 exists on the other end 4b side of the other end 4b side of the first region R1. The end portion 2Ca on the one end 4a side of the second region R2 is located on the other end 4b side of the end portion 1Cb on the other end 4b side of the first region R1.

Therefore, in the blood collection container 11C, there is no overlapping region where the first region R1 and the second region R2 overlap.

In the blood collection container 11C, the third region R3 has a region existing on one end 4a side of the end portion 1Ca on the one end 4a side of the first region R1. The end 3Ca on the one end 4a side of the third region R3 is located on the one end 4a side of the end 1Ca on the one end 4a side of the first region R1.

In the blood collection container 11C, the third region R3 has a region existing on the other end 4b side of the other end 4b side of the first region R1. The end portion 3Cb on the other end 4b side of the third region R3 is located on the other end 4b side of the end portion 1Cb on the other end 4b side of the first region R1.

Therefore, in the blood collection container 11C, there is an overlapping region R13 in which the first region R1 and the third region R3 overlap. In the blood collection vessel 11C, the overlapping region R13 coincides with the first region R1. In the blood collection vessel 11C, the overlapping region R13 is an annular region. In the blood collection vessel 11C, the layer containing the serine protease is located inside the layer containing the inorganic powder in the overlapping region R13.

In the overlapping region R13, serine protease and inorganic powder coexist.

In the blood collection container 11C, the third region R3 has a region existing on one end 4a side of the end portion 2Ca on the one end 4a side of the second region R2. The end 3Ca on the one end 4a side of the third region R3 is located on the one end 4a side of the end 2Ca on the one end 4a side of the second region R2.

In the blood collection container 11C, the end 2Cb on the other end 4b side of the second region R2 and the end 3Cb on the other end 4b side of the third region R3 exist at the same position.

Therefore, in the blood collection container 11C, there is an overlapping region R23 in which the second region R2 and the third region R3 overlap. In the blood collection vessel 11C, the overlapping region R23 coincides with the second region R2. In the blood collection vessel 11C, the overlapping region R23 is an annular region. In the blood collection vessel 11C, the layer containing the heparin neutralizer is located inside the layer containing the inorganic powder in the overlapping region R23.

FIG. 5 is a front sectional view of the blood collection container according to the fifth embodiment of the present invention.

The blood collection container 11D includes serine protease 1D (layer containing serine protease), heparin neutralizer 2D (layer containing heparin neutralizer), inorganic powder 3D (layer containing inorganic powder), and a blood collection container body. 4, a composition for separating serum 5, and a plug 6 are provided. The blood collection container body 4 has an opening at one end 4a and a bottom closed at the other end 4b. The serum separation composition 5 is housed in the bottom of the blood collection container body 4. The plug 6 is inserted into the opening of the blood collection container main body 4. Further, the blood collection container 11D includes an antifoaming agent (not shown) arranged at least at the bottom of the blood collection container main body 4. The blood collection container 11D is tubular and is a vacuum collection tube.

The serine protease 1D, the heparin neutralizer 2D, the inorganic powder 3D, and the antifoaming agent are each arranged in the blood collection container main body 4, and are attached to the inner wall surface of the blood collection container main body 4, respectively, and are attached to the inner wall surface of the blood collection container main body 4. It is arranged on the inner wall surface of No. 4.

The first region R1 is a region in which serine protease 1D is arranged. The first region R1 is an annular region.

The second region R2 is a region in which the heparin neutralizer 2D is arranged. The second region R2 is an annular region.

The third region R3 is a region in which the inorganic powder 3D is arranged. The third region R3 is an annular region.

In the blood collection container 11D, the second region R2 has a region existing on the other end 4b side of the other end 4b side of the first region R1. The end 2Db on the other end 4b side of the second region R2 is located on the other end 4b side of the end 1Db on the other end 4b side of the first region R1.

In the blood collection container 11D, the second region R2 has a region existing on one end 4a side of the end portion 1Da on the one end 4a side of the first region R1. The end portion 2Da on the one end 4a side of the second region R2 is located on the one end 4a side of the end portion 1Da on the one end 4a side of the first region R1.

Therefore, in the blood collection container 11D, there is an overlapping region R12 in which the first region R1 and the second region R2 overlap. In the blood collection vessel 11D, the overlapping region R12 coincides with the first region R1. In the blood collection vessel 11D, the overlapping region R12 is an annular region. In the blood collection vessel 11D, the layer containing the heparin neutralizer is located inside the layer containing the serine protease in the overlapping region R12.

In the blood collection container 11D, the second region R2 has a region existing on one end 4a side of the end portion 3Da on the one end 4a side of the third region R3. The end portion 2Da on the one end 4a side of the second region R2 is located on the one end 4a side of the end portion 3Da on the one end 4a side of the third region R3.

In the blood collection container 11D, the end 2Db on the other end 4b side of the second region R2 and the end 3Db on the other end 4b side of the third region R3 exist at the same position.

Therefore, in the blood collection container 11D, there is an overlapping region R23 in which the second region R2 and the third region R3 overlap. In the blood collection vessel 11D, the overlapping region R23 coincides with the third region R3. In the blood collection vessel 11D, the overlapping region R23 is an annular region. In the blood collection vessel 11D, the layer containing the heparin neutralizer is located inside the layer containing the inorganic powder in the overlapping region R23.

FIG. 6 is a front sectional view of the blood collection container according to the sixth embodiment of the present invention.

The blood collection container 11E includes serine protease 1E (layer containing serine protease), heparin neutralizer 2E (layer containing heparin neutralizer), inorganic powder 3E (layer containing inorganic powder), and a blood collection container main body. 4, a composition for separating serum 5, and a plug 6 are provided. The blood collection container body 4 has an opening at one end 4a and a bottom closed at the other end 4b. The serum separation composition 5 is housed in the bottom of the blood collection container body 4. The plug 6 is inserted into the opening of the blood collection container main body 4. Further, the blood collection container 11E includes an antifoaming agent (not shown) arranged at least at the bottom of the blood collection container main body 4. The blood collection container 11E is tubular and is a vacuum collection tube.

The serine protease 1E, the heparin neutralizer 2E, the inorganic powder 3E, and the defoaming agent are each arranged in the blood collection container main body 4 and adhere to the inner wall surface of the blood collection container main body 4, respectively, and the blood collection container main body 4 It is arranged on the inner wall surface of No. 4.

The first region R1 is a region in which the serine protease 1E is arranged. The first region R1 is an annular region.

The second region R2 is a region in which the heparin neutralizer 2E is arranged. The second region R2 is an annular region.

The third region R3 is a region in which the inorganic powder 3E is arranged. The third region R3 is an annular region.

In the blood collection container 11E, the second region R2 has a region existing on the other end 4b side of the other end 4b side of the first region R1. The end portion 2Eb on the other end 4b side of the second region R2 is located on the other end 4b side of the end portion 1Eb on the other end 4b side of the first region R1.

In the blood collection container 11E, the first region R1 has a region existing on one end 4a side of the end portion 2Ea on the one end 4a side of the second region R2. The end portion 1Ea on the one end 4a side of the first region R1 is located on the one end 4a side of the end portion 2Ea on the one end 4a side of the second region R2.

Therefore, in the blood collection container 11E, there is an overlapping region R12 in which the first region R1 and the second region R2 overlap. In the blood collection vessel 11E, the overlapping region R12 is an annular region. In the blood collection vessel 11E, the layer containing the heparin neutralizer is located inside the layer containing the serine protease in the overlapping region R12.

In the blood collection container 11E, the second region R2 has a region existing on one end 4a side of the end portion 3Ea on the one end 4a side of the third region R3. The end portion 2Ea on the one end 4a side of the second region R2 is located on the one end 4a side of the end portion 3Ea on the one end 4a side of the third region R3.

In the blood collection container 11E, the end 2Eb on the other end 4b side of the second region R2 and the end 3Eb on the other end 4b side of the third region R3 exist at the same position.

Therefore, in the blood collection container 11E, there is an overlapping region R23 in which the second region R2 and the third region R3 overlap. In the blood collection vessel 11E, the overlapping region R23 coincides with the third region R3. In the blood collection vessel 11E, the overlapping region R23 is an annular region. In the blood collection vessel 11E, the layer containing the heparin neutralizer is located inside the layer containing the inorganic powder in the overlapping region R23.

FIG. 7 is a front sectional view of the blood collection container according to the seventh embodiment of the present invention.

The blood collection container 11F includes serine protease 1F (layer containing serine protease), heparin neutralizer 2F (layer containing heparin neutralizer), inorganic powder 3F (layer containing inorganic powder), and a blood collection container body. 4, a composition for separating serum 5, and a plug 6 are provided. The blood collection container body 4 has an opening at one end 4a and a bottom closed at the other end 4b. The serum separation composition 5 is housed in the bottom of the blood collection container body 4. The plug 6 is inserted into the opening of the blood collection container main body 4. Further, the blood collection container 11F includes an antifoaming agent (not shown) arranged at least at the bottom of the blood collection container main body 4. The blood collection container 11F is tubular and has a vacuum collection tube.

The serine protease 1F, heparin neutralizer 2F, inorganic powder 3F, and defoamer are each arranged in the blood collection container body 4 and adhere to the inner wall surface of the blood collection container body 4, respectively. It is arranged on the inner wall surface of No. 4.

The first region R1 is a region in which serine protease 1F is arranged. The first region R1 is an annular region.

The second region R2 is a region in which the heparin neutralizer 2F is arranged. The second region R2 is an annular region.

The third region R3 is a region in which the inorganic powder 3F is arranged. The third region R3 is an annular region.

In the blood collection container 11F, the second region R2 has a region existing on the other end 4b side of the other end 4b side of the first region R1. In the blood collection container 11F, the entire second region R2 exists on the other end 4b side of the other end 4b side of the first region R1. The end portion 2Fa on the one end 4a side of the second region R2 is located on the other end 4b side of the end portion 1Fb on the other end 4b side of the first region R1.

Therefore, in the blood collection container 11F, there is no overlapping region where the first region R1 and the second region R2 overlap.

In the blood collection container 11F, the third region R3 has a region existing on one end 4a side of the end portion 1F on the one end 4a side of the first region R1. The end 3F on the one end 4a side of the third region R3 is located on the one end 4a side of the end 1F on the one end 4a side of the first region R1.

In the blood collection container 11F, the third region R3 has a region existing on the other end 4b side of the other end 4b side of the first region R1. The end 3Fb on the other end 4b side of the third region R3 is located on the other end 4b side of the other end 4b side end 1Fb of the first region R1.

Therefore, in the blood collection container 11F, there is an overlapping region R13 in which the first region R1 and the third region R3 overlap. In the blood collection container 11F, the overlapping region R13 is an annular region. In the blood collection vessel 11F, the layer containing the serine protease is located inside the layer containing the inorganic powder in the overlapping region R13.

In the overlapping region R13, serine protease and inorganic powder coexist.

In the blood collection container 11F, the third region R3 has a region existing on one end 4a side of the end portion 2F on the one end 4a side of the second region R2. The end 3F on the one end 4a side of the third region R3 is located on the one end 4a side of the end 2F on the one end 4a side of the second region R2.

In the blood collection container 11F, the second region R2 has a region existing on the other end 4b side of the other end 4b side of the third region R3. The end portion 2Fb on the other end 4b side of the second region R2 is located on the other end 4b side of the end portion 3Fb on the other end 4b side of the third region R3.

Therefore, in the blood collection container 11F, there is an overlapping region R23 in which the second region R2 and the third region R3 overlap. In the blood collection container 11F, the overlapping region R23 is an annular region. In the blood collection vessel 11F, the layer containing the heparin neutralizer is located inside the layer containing the inorganic powder in the overlapping region R23.

In the blood collection container according to the present invention, the end of the first region R1 on one end side (one end side of the blood collection container body) is the end of the second region R2 on one end side (one end side of the blood collection container body). It may be located on one end side of the portion, or may be located on the other end side. Further, in the blood collection container according to the present invention, the end portion on one end side of the first region R1 may coincide with the end portion on the one end side of the second region R2.

In the blood collection container according to the present invention, the end of the first region R1 on one end side (one end side of the blood collection container body) is the end of the third region R3 on one end side (one end side of the blood collection container body). It may be located on one end side of the portion, or may be located on the other end side. Further, in the blood collection container according to the present invention, the end portion on one end side of the first region R1 may coincide with the end portion on the one end side of the third region R3.

In the blood collection container according to the present invention, the end of the second region R2 on one end side (one end side of the blood collection container body) is the end of the third region R3 on one end side (one end side of the blood collection container body). It may be located on one end side of the portion, or may be located on the other end side. Further, in the blood collection container according to the present invention, the end portion of the second region R2 on the one end side may coincide with the end portion of the third region R3 on the one end side.

In the blood collection container according to the present invention, the other end of the second region R2 (the other end of the blood collection container body) is the other end of the third region R3 (the other end of the blood collection container body). It may be located on one end side of the end portion on the side), or may be located on the other end side. Further, in the blood collection container according to the present invention, the other end of the second region R2 may coincide with the other end of the third region R3.

In the blood collection container according to the present invention, the first region R1, the second region R2, the third region R3, the overlapping region R12, the overlapping region R23, and the overlapping region R13 may be cyclic regions, respectively. , It does not have to be an annular region. The shapes of the first region R1, the second region R2, and the third region R3 are appropriately changed depending on, for example, the shape of the blood collection container body and the like.

In the blood collection container according to the present invention, the layer containing the heparin neutralizer may be located inside or outside the layer containing the serine protease in the overlapping region R12. In the blood collection vessel according to the present invention, it is preferable that the layer containing the heparin neutralizer is located inside the layer containing the serine protease in the overlapping region R12.

In the blood collection container according to the present invention, the layer containing the heparin neutralizer may be located inside or outside the layer containing the inorganic powder in the overlapping region R23. In the blood collection container according to the present invention, it is preferable that the layer containing the heparin neutralizer is located inside the layer containing the inorganic powder in the overlapping region R23. In this case, the amount of the heparin neutralizing agent that comes into contact with blood containing heparin can be increased, and the effect of the present invention can be exhibited even more effectively.

In the blood collection container according to the present invention, when blood is collected by collecting blood or dispensing a blood sample with the other end side of the blood collection container as the lower side, the blood level is higher than the liquid level of the collected blood. It is preferable that the first region R1 exists at (one end side of the blood collection container body).

Hereinafter, the blood collection container according to the present invention will be described in more detail.

(Serine protease: first region R1)
The serine protease is placed in the blood collection container body. The serine protease is preferably adhered to the inner wall surface of the blood collection container body. In this case, the serine protease may be attached to the inner wall surface of the blood collection container body via, for example, a water-soluble binder described later. Only one type of the serine protease may be used, or two or more types may be used in combination. The first region R1 is the region where the serine protease is located.

Examples of the serine protease include thrombin, thrombin-like enzyme, trypsin, fibrinogen-degrading enzyme and the like. Examples of the thrombin-like enzyme include snake venom and ecarin.

From the viewpoint of effectively coagulating blood, the serine protease is preferably thrombin, thrombin-like enzyme, or fibrinogen-degrading enzyme, more preferably thrombin or thrombin-like enzyme, and further preferably thrombin. preferable. The thrombin-like enzyme is preferably snake venom or ecarin.

In the blood collection container, the content of the serine protease is preferably 0.5 units or more, more preferably 1 unit or more, preferably 50 units or less, and more preferably 20 units or less per 1 mL of collected blood. .. When the content of the serine protease is not less than the above lower limit and not more than the above upper limit, the blood coagulation reaction can be effectively promoted, and the effect of the present invention can be more effectively exerted.

(Heparin Neutralizer: Second Region R2)
The heparin neutralizer is placed in the blood collection container body. The heparin neutralizer is preferably adhered to the inner wall surface of the blood collection container body. In this case, the heparin neutralizer may be attached to the inner wall surface of the blood collection container body via, for example, a water-soluble binder described later, and the heparin neutralizer alone may be used for blood collection. It may adhere to the inner wall surface of the container body. Only one kind of the above-mentioned heparin neutralizer may be used, or two or more kinds thereof may be used in combination. The second region R2 is a region in which the heparin neutralizer is arranged.

The heparin neutralizer may be any one that can be used as a heparin neutralizer, and examples thereof include amine salts and organic compounds having a quaternary nitrogen atom. The amine salt and the organic compound having a quaternary nitrogen atom can adsorb and neutralize heparin in blood to inactivate heparin.

The amine salt may be a primary amine salt, a secondary amine salt, or a tertiary amine salt. The amine constituting the amine salt may be a linear amine, a cyclic amine, a low molecular weight compound, or a high molecular weight compound having a low molecular weight repeating structural unit. There may be. The amine constituting the amine salt may be a primary amine, a secondary amine, or a tertiary amine. Further, the acid constituting the amine salt may be an inorganic acid or an organic acid. Examples of the inorganic acid include hydrohalic acid such as hydrochloric acid, sulfuric acid, sulfurous acid and the like, and examples of the organic acid include formic acid and acetic acid. The amine salt may have an acetyl group, an imino group, or an ether group. The amine salt may be an intramolecular salt.

Preferred specific examples of the amine salt include, for example, hexadecyldimethylamine hydrochloride represented by the following formula (1), tetradecyldi (aminoethyl) glycine represented by the following formula (2), and the like.

The organic compound having a quaternary nitrogen atom may be a linear compound, a cyclic compound, a low molecular weight compound, or a polymer having a low molecular weight repeating structural unit. It may be a compound. Examples of the organic compound having a quaternary nitrogen atom include tetraalkylammonium and the like. The organic compound having a quaternary nitrogen atom may have an alkyl group, an aryl group, an imino group, or an ether group. Good.

Preferred specific examples of the organic compound having a quaternary nitrogen atom include dodecyltrimethylammonium chloride represented by the following formula (3).

Further, examples of the organic compound having a quaternary nitrogen atom include a polymer having a quaternary nitrogen in addition to the above-mentioned compound having a relatively small molecular weight. Examples of the polymer having quaternary nitrogen include polycations having a repeating structural unit represented by the following formula (4).

In the above formula (4), R ₁ to R ₄ represent a hydrogen atom or an alkyl group, respectively, X represents a halogen atom or an acid group, and Y represents an alkylene group or a group in which a sulfonyl group is bonded to an alkylene group. In the above formula (4), R ₁ and R ₂ are preferably alkyl groups having 5 or less carbon atoms, respectively, and preferably methyl groups or ethyl groups. In the above formula (4), _{it is preferable that R 3} and R ₄ are hydrogen atoms, respectively.

In the polycation having the structural unit represented by the above formula (4), the number of repetitions of the structural unit represented by the formula (4) is preferably 5 or more, preferably 2000 or less. The polycation having a structural unit represented by the above formula (4) may partially have a structural unit in which _{R 1} or R _{2 of the above formula (4) is a hydrogen atom.}

The polycation having a structural unit represented by the above formula (4) is preferably a polycation having a structural unit represented by the following formula (5) or the following formula (6), and is preferably represented by the following formula (6). More preferably, it is a polycation having the structure represented. The polycation having the structure represented by the following formula (6) is polyamine salphon.

The polycation having the structural unit represented by the above formula (5) may be a polycation represented by the following formula (7) or a polycation represented by the following formula (8). , It may be a polycation represented by the following formula (9), or it may be a polycation represented by the following formula (10). Further, the polycation having the structural unit represented by the above formula (4) is the above formula (5), the above formula (6), the following formula (7), the following formula (8), the following formula (9) or the following formula. One or both of the two methyl groups in the formula (10) may be a polycation which is an alkyl group such as an ethyl group.

Further, the polymer having quaternary nitrogen is a polymer having a group containing quaternary nitrogen instead of the six-membered ring containing quaternary nitrogen of the above formulas (4) to (10). May be good. The polymer having quaternary nitrogen contains a five-membered ring containing quaternary nitrogen and a quaternary nitrogen instead of the six-membered ring containing quaternary nitrogen of the above formulas (4) to (10). It may be a polymer having a four-membered ring and a three-membered ring containing quaternary nitrogen.

In the blood collection container, the content of the heparin neutralizer is appropriately adjusted according to the type of the heparin neutralizer, the amount of blood collected, and the heparin concentration in the blood. In the blood collection container, the content of the heparin neutralizer is preferably 1 × 10 ^-7 g or more, more preferably 5 × 10 ^-6 g or more, and further preferably 1 × 10 per 1 mL of collected blood. ^{It is -5} g or more, particularly preferably 1.5 × 10 ^-5 g or more. In the blood collection container, the content of the heparin neutralizer is preferably 1 × 10 ^-1 g or less, more preferably 1 × 10 ^-2 g or less, and even more preferably 1 × per 1 mL of collected blood. It is 10 ^-4 g or less, more preferably 5 × 10 ^-5 g or less, and particularly preferably 3.5 × 10 ^-5 g or less. When the content of the heparin neutralizer is at least the above lower limit and at least the above upper limit, the effect of the present invention can be exhibited even more effectively. In the blood collection container, the content of the heparin neutralizer ^{is preferably 1 × 10 -5} g or more and 5 × 10 ^-5 g or less, and 1.5 × 10 ^{-5 g or less, per 1 mL of collected blood.} It is more preferably g or more and 3.5 × ^{10-5 g or less.} In this case, the effect of the present invention can be exerted even more effectively.

(Inorganic powder: third region R3)
The blood collection container preferably includes an inorganic powder arranged in the blood collection container body. The inorganic powder is preferably adhered to the inner wall surface of the blood collection container body. In this case, the inorganic powder may be attached to the inner wall surface of the blood collection container main body via, for example, a water-soluble binder described later. Only one kind of the above-mentioned inorganic powder may be used, or two or more kinds may be used in combination. The third region R3 is a region in which the inorganic powder is arranged.

Examples of the inorganic powder include silica powder, glass powder, kaolin powder, celite powder, bentonite powder and the like. Only one kind of the above-mentioned inorganic powder may be used, or two or more kinds may be used in combination.

From the viewpoint of coagulating blood well, the inorganic powder is preferably silica powder, more preferably porous silica powder.

The average particle size of the inorganic powder is preferably 1 mm or less, more preferably 100 μm or less, still more preferably 50 μm or less, and particularly preferably 10 μm or less. When the average particle size of the inorganic powder is not more than the above upper limit, blood can be satisfactorily coagulated in a short time.

The average particle size of the inorganic powder is an average diameter measured on a volume basis, and is a value of a median diameter (D50) of 50%. The volume average particle size (D50) can be measured by a laser diffraction / scattering method, an image analysis method, a Coulter method, a centrifugal sedimentation method, or the like. The volume average particle size (D50) is preferably determined by measurement by a laser diffraction / scattering method or an image analysis method.

The amount of flax oil absorbed by the inorganic powder is preferably 20 ml / 100 g or more, preferably 40 ml / 100 g or less. When the amount of flax oil absorbed by the inorganic powder is equal to or greater than the above lower limit and equal to or lower than the above upper limit, the effect of the present invention can be more effectively exhibited.

The amount of flax oil absorbed by the inorganic powder is measured in accordance with JIS K-5101.

The BET specific surface area of the inorganic powder is preferably 5000 cm ² / g or more, preferably 30,000 cm ² / g or less. When the BET specific surface area of the inorganic powder is at least the above lower limit and at least the above upper limit, the effect of the present invention can be exhibited even more effectively.

For the BET specific surface area of the inorganic powder, the amount of gas adsorbed on the surface of the inorganic powder, the equilibrium pressure at that time, and the saturated vapor pressure of the adsorbed gas are used to determine the amount of gas that covers the surface as a monolayer. It can be calculated by multiplying the average cross-sectional area of the adsorbed gas molecules. As the adsorbed gas, nitrogen gas, oxygen gas, argon gas, methane gas and the like can be used. With the BET specific surface area, it is possible to measure the surface area including the pores, which cannot be measured by measuring the amount of flax oil absorbed.

In the blood collection container, the content of the inorganic powder is preferably 1 × 10 ^-6 g or more, more preferably 5 × 10 ^-5 g or more, preferably 1 × 10 ^-2- g, per 1 mL of collected blood. Hereinafter, it is more preferably 1 × 10 ^-3 g or less. When the content of the inorganic powder is not less than the above lower limit and not more than the above upper limit, blood can be satisfactorily coagulated in a short time, and the effect of the present invention can be more effectively exhibited. If the content of the inorganic powder exceeds the above upper limit, it may affect the serum test result.

In the first region, the serine protease may be arranged in layers or may be formed in islands such as dots. In the second region, the heparin neutralizer may be arranged in layers or may be formed in islands such as dots. In the third region, the inorganic powder may be arranged in layers or may be formed in islands such as dots.

Let L be the distance between the one end and the other end of the blood collection container body. The first region R1 preferably exists in at least a part of the region between the position of 0.05 L and the position of 0.40 L from one end to the other end, and the position of 0.06 L. It is more preferably present in at least a partial region between the 0.35 L position and even more preferably in at least a partial region between the 0.07 L position and the 0.30 L position. It is particularly preferred to be present in at least a portion of the region between the 0.07 L position and the 0.25 L position. The first region R1 preferably exists on the one end side of the 0.40 L position from the one end to the other end, and more preferably exists on the one end side of the 0.35 L position. It is more preferable that it exists on the one end side than the position of 0.30 L, and it is particularly preferable that it exists on the one end side of the position of 0.25 L. In this case, the effect of the present invention can be exerted even more effectively.

The second region R2 preferably exists in at least a part of the region between the position of 0.40 L and the position of 0.90 L from one end to the other end, and the position of 0.45 L. It is more preferably present in at least a partial region between the 0.85 L position and even more preferably in at least a partial region between the 0.50 L position and the 0.85 L position. In this case, the effect of the present invention can be exerted even more effectively.

The third region R3 preferably exists in at least a part of the region between the position of 0.01 L and the position of 1.00 L from one end to the other end, and the position of 0.02 L. It is more preferably present in at least a partial region between the 0.90 L position and even more preferably in at least a partial region between the 0.03 L position and the 0.85 L position. In this case, the effect of the present invention can be exerted even more effectively.

The overlapping region R12 in which the first region R1 and the second region R2 overlap does not exist or exists. The overlapping region R12 may or may not be present. From the viewpoint of exerting the effect of the present invention even more effectively, it is preferable that the overlapping region R12 does not exist.

When the overlapping region R12 is present, the end portion of the overlapping region R12 on the one end side and the other end side of the overlapping region R12 with respect to the distance between the end portion on the one end side and the end portion on the other end side of the second region R2. Ratio of distance to the end (distance between the end on the one end side of the overlapping region R12 and the end on the other end side / the end on the one end side and the end on the other end side of the second region R2) The distance from) is the ratio (R12 / R2). The above ratio (R12 / R2) is preferably 0.2 or less, more preferably 0.1 or less, still more preferably 0.05 or less, and particularly preferably 0.01 or less. In this case, the effect of the present invention can be exerted even more effectively.

The distance between the end on one end side of the overlapping region R12 and the end on the other end side and the distance between the end on one end side and the end on the other end side of the second region R2 are blood. This is the distance in the direction connecting the one end of the sampling container body and the other end.

The overlapping region R13 in which the first region R1 and the third region R3 overlap does not exist or exists. The overlapping region R13 may or may not be present.

When the overlapping region R13 exists, the end portion of the overlapping region R13 on the one end side and the other end side of the overlapping region R13 with respect to the distance between the end portion on the one end side and the end portion on the other end side of the third region R3. Ratio of distance to the end (distance between the end on the one end side of the overlapping region R13 and the end on the other end side / the end on the one end side and the end on the other end side of the third region R3) The distance from) is the ratio (R13 / R3). The ratio (R13 / R3) is preferably 0.40 or less, more preferably 0.35 or less, still more preferably 0.30 or less, and particularly preferably 0.25 or less. In this case, the effect of the present invention can be exerted even more effectively.

The distance between the end on one end side of the overlapping region R13 and the end on the other end side and the distance between the end on one end side and the end on the other end side of the third region R3 are blood. This is the distance in the direction connecting the one end of the sampling container body and the other end.

The overlapping region R23 in which the second region R2 and the third region R3 overlap does not exist or exists. The overlapping region R23 may or may not be present.

When the overlapping region R23 exists, the end portion of the overlapping region R23 on the one end side and the other end side of the overlapping region R23 with respect to the distance between the end portion on the one end side and the end portion on the other end side of the third region R3. Ratio of distance to the end (distance between the end on the one end side of the overlapping region R23 and the end on the other end side / the end on the one end side and the end on the other end side of the third region R3) The distance from) is the ratio (R23 / R3). The above ratio (R23 / R3) is preferably 0.6 or less, more preferably 0.3 or less, still more preferably 0.1 or less. In this case, the effect of the present invention can be exerted even more effectively.

The distance between the end on one end side of the overlapping region R23 and the end on the other end side and the distance between the end on one end side and the end on the other end side of the third region R3 are blood. This is the distance in the direction connecting the one end of the sampling container body and the other end.

(Defoamer)
The blood collection container preferably includes an antifoaming agent arranged in the blood collection container body. The defoaming agent is preferably adhered to the inner wall surface of the blood collection container body. As the defoaming agent, only one kind may be used, or two or more kinds may be used in combination.

Examples of the defoaming agent include polyoxyalkylenes and polyoxyalkylene derivatives. Examples of the polyoxyalkylene derivative include polyoxyalkylene ether and the like.

Examples of the polyoxyalkylene ether include polyoxypropylene, polyoxypropylene glyceryl ether, polyoxyethylene, polyoxyethylene glyceryl ether, poly (oxyethylene / oxypropylene), poly (oxyethylene / oxypropylene) glyceryl ether and the like. Can be mentioned.

The region where the defoaming agent is arranged is defined as the fourth region R4, and the distance between the one end and the other end of the blood collection container body is L.

The fourth region R4 preferably exists in at least a part of the region between the position of 0.05 L and the position of 1.00 L from one end to the other end, and the position of 0.07 L. It is more preferably present in at least a partial region between the 0.90 L position and even more preferably in at least a partial region between the 0.10 L position and the 0.85 L position. The defoaming agent is preferably placed at least at the bottom of the blood collection container. In this case, when the blood is collected, the blood comes into good contact with the defoaming agent, and the generation of air bubbles after the blood collection can be suppressed, and as a result, the generation of blood clots in which the air bubbles bite occurs. It can be suppressed even more effectively.

Note that there may or may not be an overlapping region in which the fourth region R4 and the first region R1 overlap. The overlapping region where the fourth region R4 and the second region R2 overlap may or may not exist. An overlapping region in which the fourth region R4 and the third region R3 overlap may or may not exist.

In the blood collection container, the content of the antifoaming agent is preferably 2.0 × 10 ^-3 mg or more, more preferably 3.0 × 10 ^-3 mg or more, preferably 0 per 1 mL of collected blood. It is .2 mg or less, more preferably 0.11 mg or less. When the content of the defoaming agent is at least the above lower limit, the defoaming effect can be further enhanced. When the content of the defoaming agent is not more than the above upper limit, the generation of insoluble matter caused by the defoaming agent can be suppressed, and therefore, the nozzle for collecting a sample may be clogged with the insoluble matter at the time of clinical examination. It is possible to suppress the occurrence of troubles during clinical examinations such as.

(Composition for serum separation)
The blood collection container preferably includes a serum separation composition contained in the bottom of the blood collection container body.

As the above-mentioned serum separation composition, a conventionally known serum separation composition can be used. Examples of the serum separation composition include the serum separation composition described in WO2011 / 105151A1 and the like.

The above serum separation composition is used for the purpose of preventing component transfer between the blood clot layer and the serum layer by moving between the serum layer and the blood clot layer to form a septum during centrifugation.

(Other details of blood collection container)
The material of the blood collection container body is not particularly limited. The material of the blood collection container body is a thermoplastic resin such as polyethylene, polypropylene, polystyrene, polyethylene terephthalate, polymethyl methacrylate, or polyacrylonitrile; a thermosetting resin such as an unsaturated polyester resin, an epoxy resin, or an epoxy-acrylate resin; Modified natural resins such as cellulose acetate, cellulose propionate, ethyl cellulose and ethyl chitin; silicate glass such as soda lime glass, phosphoric acid glass and borosilicate glass, and glass such as quartz glass can be mentioned. As the material of the blood collection container body, only one kind may be used, or two or more kinds may be used in combination.

The blood collection container is preferably provided with a plug. As the plug body, a conventionally known plug body can be used. The plug body is preferably a plug body made of a material and a shape that can be attached to the opening of the blood collection container body in an airtight and liquid-tight manner. The plug body is preferably configured so that a blood collection needle can be pierced.

Examples of the plug body include a plug body having a shape that fits into the opening of the blood collection container body, a sheet-shaped seal plug body, and the like.

Further, the stopper body may be a stopper body including a stopper body such as a rubber stopper and a cap member made of plastic or the like. In this case, it is possible to reduce the risk of blood coming into contact with the human body when the plug is pulled out from the opening of the blood collection container body after blood collection.

Examples of the material of the stopper body (or the stopper body) include synthetic resin, elastomer, rubber, metal leaf and the like. Examples of the rubber include butyl rubber and halogenated butyl rubber. Examples of the metal foil include aluminum foil and the like. From the viewpoint of enhancing the sealing property, the material of the plug body (or the plug body) is preferably butyl rubber. The stopper body (or the stopper body) is preferably a butyl rubber stopper.

The main body of the blood collection container is preferably the main body of the blood collection tube. The blood collection container is preferably a blood collection tube.

The internal pressure of the blood collection container is not particularly limited. The blood collection container may be a vacuum blood collection container (vacuum blood collection tube) that is sealed by the plug body after the inside is exhausted. In the case of a vacuum blood collection tube, a certain amount of blood can be easily collected regardless of the technical difference of the blood collector.

From the viewpoint of preventing bacterial infection, it is preferable that the inside of the blood collection container is sterilized according to the standards described in ISO and JIS.

The blood collection container contains a first composition containing a serine protease, a second composition containing a heparin neutralizer,, if necessary, a third composition containing an inorganic powder, and an antifoaming agent. It can be produced by arranging the fourth composition containing the mixture on the inner wall surface of the blood collection container body. As the method of the above arrangement, known techniques such as coating, spraying, and adhesion to the inner wall can be adopted.

The region where the first composition is arranged corresponds to the first region R1 in the blood collection container. The region in which the second composition is arranged corresponds to the second region R2 in the blood collection container. The region in which the third composition is arranged corresponds to the third region R3 in the blood collection container. The region in which the fourth composition is arranged corresponds to the fourth region R4 in the blood collection container. The region where both the first composition and the second composition are overlapped corresponds to the overlapping region R12 in the blood collection container. The region where both the first composition and the third composition are overlapped corresponds to the overlapping region R13 in the blood collection container. The region where both the second composition and the third composition are overlapped corresponds to the overlapping region R23 in the blood collection container.

The above coating method is not particularly limited. Examples of the coating method include spray coating and dipping coding method. It is preferable that each of the above compositions is applied to the inner wall surface of the blood collection container body and then dried.

Further, before coating and drying each of the above compositions, or after coating and drying, the composition for serum separation is contained, and after each of the above compositions is coated and dried, the plug body is placed in the blood collection container body. It is preferable to manufacture the blood collection container by attaching it to the opening.

The coating order (arrangement order) of the first composition, the second composition, the third composition, and the fourth composition is not particularly limited. From the viewpoint of increasing the amount of the heparin neutralizer that comes into contact with blood containing heparin, the second composition is applied and dried after the application and drying of the third composition and the fourth composition. Is preferable. It is preferable to apply and dry the second composition after the application and drying of the first composition, the third composition and the fourth composition.

The first composition, the second composition, the third composition, and the fourth composition are water, an organic solvent, a water-soluble binder, an antifibrinolytic solvent, an antiplasmin agent, and blood clot peeling, respectively. It may contain other components such as components. In this case, the first region R1, the second region R2, the third region R3, and the fourth region R4 may each include the other components described above.

Examples of the organic solvent include methanol, ethanol, butanol, isopropanol, hexane and the like. Only one kind of the organic solvent may be used, or two or more kinds may be used in combination.

Examples of the water-soluble binder include polyvinyl alcohol, polyvinylpyrrolidone, acrylic acid-based copolymers, polyoxyalkylene block copolymers, and the like. Only one kind of the water-soluble binder may be used, or two or more kinds thereof may be used in combination.

Examples of the anti-firing solvent and the anti-plasmin agent include aprotinin, soybean trypsin inhibitor, ε-aminocaproic acid, p-aminomethylbenzoic acid, aminomethylcyclohexanecarboxylic acid and the like. As the anti-ray solvent and the anti-plasmin agent, only one type may be used, or two or more types may be used in combination.

The anti-ray solvent and the anti-plasmin agent are preferably used in clinically recommended amounts. Aprotinin is preferably used, for example, in an amount of about 100 KIU to 600 KIU (unit) per 1 mL of blood collected. The soybean trypsin inhibitor is preferably used, for example, at about 500 IU to 4000 IU (unit) per 1 ml of blood collected. Each ε- aminocaproic acid, p- aminobenzoic acid and aminomethyl cyclohexane carboxylic acid, for example, per blood 1ml being taken, it is preferably used in about ^¹⁰ -8 g ~ ¹⁰ ^-2 g.

Examples of the blood clot peeling component include silicone oil, polyvinylpyrrolidone, polyvinyl alcohol, polyoxyalkylene, and derivatives thereof. Only one type of the blood clot peeling component may be used, or two or more types may be used in combination. From the viewpoint of effectively suppressing the adhesion of blood to the inner wall surface of the blood collection container, the main body of the blood collection container contains silicone oil, polyvinylpyrrolidone, polyvinyl alcohol, polyoxyalkylene, or these as the blood clot peeling component. It is preferable that the derivative of the above is arranged. Examples of the silicone oil include a water-soluble type modified silicone oil, which is preferably used. Examples of the polyoxyalkylene and its derivatives include polyoxypropylene butyl ether, polyoxyethylene butyl ether, polyoxypropylene glyceryl ether, and polyoxyethylene glyceryl ether, which are preferably used. In addition, polyoxypropylene glyceryl ether is a component corresponding to an antifoaming agent.

Hereinafter, the present invention will be described in more detail with reference to examples. The present invention is not limited to the following examples.

The following blood collection container body was prepared.

Blood collection container body having the shape shown in FIG. 1 Inner diameter 10.8 mm x length 100 mm (length: distance between one end (open end) and the other end)
Material: Polyethylene terephthalate

The following plugs were prepared.

Plug body with the shape shown in Fig. 1 Rubber plug (Material: Butyl rubber)

The following composition for serum separation was prepared.

Composition for serum separation (thixotropy separating agent, manufactured by Sekisui Chemical Co., Ltd.)

The following materials for the first composition, the second composition, the third composition and the fourth composition were prepared.

(Serine protease)
Thrombin ("Thrombin Ito" manufactured by Ito Pharmaceutical Co., Ltd.)

(Heparin neutralizer)
Polyamine salphon (5) (polycation having a structure represented by the above formula (5)) (“PAS-H-5L” manufactured by Nitto Boseki Co., Ltd.)
Polyamine salphon (6) (polycation having a structure represented by the above formula (6)) (“PAS-A-5” manufactured by Nitto Boseki Co., Ltd.)
Polyamine salphon (7) (polycation having a structure represented by the above formula (7)) (“PAS-J-81” manufactured by Nitto Boseki Co., Ltd.)
Polyamine salphon (8) (polycation having a structure represented by the above formula (8)) (“PAS-2351” manufactured by Nitto Boseki Co., Ltd.)

(Inorganic powder)
Silica powder (manufactured by UNIMIN SPECIALTY MINERAL, average particle size 5 μm)

(Defoamer)
Polyoxypropylene glyceryl ether ("Adeka Polyester G-4000" manufactured by ADEKA CORPORATION)

(Water-soluble binder)
Polyvinylpyrrolidone ("PVP-K30" manufactured by Wako Pure Chemical Industries, Ltd.)

The first composition was prepared as follows.

175,000 units of thrombin, 0.1 g of polyvinylpyrrolidone, and 0.6 g of β-alanine were completely dissolved in 10 g of water to obtain the first composition.

The second compositions A to E were prepared as follows.

Preparation of the second composition A:
0.36 g of heparin neutralizer (polyamine salfone (6)) and 0.8 g of polyvinylpyrrolidone were completely dissolved in 100 g of water to obtain a second composition A.

Preparation of the second composition B:
0.4 g of a heparin neutralizer (polyamine salfone (6)) and 0.8 g of polyvinylpyrrolidone were completely dissolved in 50 g of water to obtain a second composition B.

Preparation of the second composition C:
0.36 g of heparin neutralizer (polyamine salfone (5)) and 0.8 g of polyvinylpyrrolidone were completely dissolved in 100 g of water to obtain a second composition C.

Preparation of the second composition D:
0.36 g of heparin neutralizer (polyamine salfone (7)) and 0.8 g of polyvinylpyrrolidone were completely dissolved in 100 g of water to obtain a second composition D.

Preparation of the second composition E:
0.36 g of heparin neutralizer (polyamine salfone (8)) and 0.8 g of polyvinylpyrrolidone were completely dissolved in 100 g of water to obtain a second composition E.

The third composition was prepared as follows.

2.5 g of silica powder and 1.5 g of polyvinylpyrrolidone were mixed with 100 g of water to obtain a third composition.

The fourth composition was prepared as follows.

0.3 g of polyoxypropylene glyceryl ether was mixed with 100 g of water to obtain a fourth composition.

Composition X was prepared as follows.

240,000 units of thrombin, 0.36 g of heparin neutralizer (polyamine salfone (6)), 0.8 g of polyvinylpyrrolidone, and 1.2 g of β-alanine were completely dissolved in 100 g of water. , Composition X was obtained.

(Example 1)
0.9 g of the serum separation composition was contained in the bottom of the blood collection container body. Next, the second composition shown in Table 1 was spray-applied to the area shown in Table 1 on the inner wall surface of the blood collection container body, and then dried. The first composition was then spray-coated on the areas shown in Table 1 and then dried. Next, the blood collection container body was depressurized to 13 kPa and sealed with a plug to prepare a blood collection container (vacuum blood collection tube).

(Example 2)
0.9 g of the serum separation composition was contained in the bottom of the blood collection container body. Next, the fourth composition was spray-applied to the area shown in Table 1 on the inner wall surface of the blood collection container body, and then dried. Then, the second composition shown in Table 1 was spray-coated on the area shown in Table 1 and then dried. The first composition was then spray-coated on the areas shown in Table 1 and then dried. A blood collection container (vacuum blood collection tube) was prepared in the same manner as in Example 1 except for these.

(Example 3)
A blood collection container (vacuum blood collection tube) was prepared in the same manner as in Example 1 except that the type of the second composition was changed as shown in Table 1.

(Example 4)
The third composition was spray-applied to the area shown in Table 1 on the inner wall surface of the blood collection container body, and then dried. The fourth composition was then spray-coated on the areas shown in Table 1 and then dried. Then, the second composition shown in Table 1 was spray-coated on the area shown in Table 1 and then dried. The first composition was then spray-coated on the areas shown in Table 1 and then dried. A blood collection container (vacuum blood collection tube) was prepared in the same manner as in Example 1 except for these.

(Examples 5 to 8)
A blood collection container (vacuum blood collection tube) was prepared in the same manner as in Example 4 except that the type of the second composition was changed as shown in Table 1.

(Example 9)
The third composition was spray-applied to the area shown in Table 1 on the inner wall surface of the blood collection container body, and then dried. The fourth composition was then spray-coated on the areas shown in Table 1 and then dried. The first composition was then spray-coated on the areas shown in Table 1 and then dried. Then, the second composition shown in Table 1 was spray-coated on the region shown in Table 1, and then immediately dried before the first composition was diffused. A blood collection container (vacuum blood collection tube) was prepared in the same manner as in Example 1 except for these.

(Examples 10 to 13)
The blood collection container (vacuum collection) was obtained in the same manner as in Example 9 except that the type of the second composition was changed as shown in Table 1 and the area to which the composition was applied was changed as shown in Table 1. Blood vessel) was prepared.

(Example 14)
The third composition was spray-applied to the area shown in Table 1 on the inner wall surface of the blood collection container body, and then dried. The fourth composition was then spray-coated on the areas shown in Table 1 and then dried. Then, the second composition shown in Table 1 was spray-coated on the region shown in Table 1, and then dried before the second composition was diffused. The first composition was then spray-coated on the areas shown in Table 1 and then dried. A blood collection container (vacuum blood collection tube) was prepared in the same manner as in Example 1 except for these.

(Comparative Example 1)
A blood collection container (vacuum blood collection tube) was prepared in the same manner as in Example 4 except that the area to which the composition was applied was changed as shown in Table 1.

(Comparative Example 2)
The composition X was spray-applied to the area shown in Table 3 on the inner wall surface of the blood collection container body, and then dried. A blood collection container (vacuum blood collection tube) was prepared in the same manner as in Example 1 except for these.

(Evaluation)
(1) Frequency of occurrence of blood clots bitten by bubbles and frequency of fibrin production in serum Blood prepared so that the concentration of heparin was 1 unit / mL was prepared. 5 mL of this blood was collected in a 10 mL syringe (without a needle, "JS-S10C" manufactured by JMS), and used in a Transfer Device ("REF364880" manufactured by BD) in the obtained blood collection container (vacuum blood collection tube). It was collected and mixed 5 times. Then, the blood collection container was allowed to stand for 20 minutes. The blood collection vessel was then centrifuged at 1500 G for 10 minutes. The blood collection container after centrifugation was observed with the naked eye, and the presence or absence of blood clots in which bubbles were caught and the presence or absence of fibrin in serum were determined according to the following criteria. In addition, each evaluation was performed by collecting the blood of 6 persons.

(1-1) Frequency and size of blood clots bitten by bubbles Six blood collection containers were observed to observe whether or not blood clots bitten by bubbles were generated. When a blood clot that was bitten by bubbles was generated, the size of the blood clot that was bitten by bubbles was classified into the following levels 1 to 3, and the number was calculated. When no blood clot with bubbles was generated, it was classified as level 0.

Level 0: No blood clots bitten by bubbles Level 1: Maximum length of blood clots bitten by bubbles is 1 cm or less Level 2: Maximum length of blood clots bited by bubbles exceeds 1 cm 2 cm or less Level 3: The maximum length of the blood clot that the bubbles bite exceeds 2 cm

(1-2) Frequency of fibrin production in serum and its size Six blood collection containers were observed to observe whether or not fibrin production was observed in serum. When the production of fibrin was observed in serum, the size of fibrin was classified into the following levels 1 to 3, and the number of fibrin was determined. When fibrin production was not observed in serum, it was classified as level 0.

Level 0: No fibrin production observed in serum Level 1: Maximum diameter of fibrin produced in serum is 1 cm or less Level 2: Maximum diameter of fibrin produced in serum is more than 1 cm and 2 cm or less Level 3: Fibrin produced in serum Maximum diameter exceeds 2 cm

The configuration and results are shown in Tables 1 to 4. Table 1 shows a diagram in which the positional relationships of the first region, the second region, and the third region are similar. Further, in Table 2, the distance is the distance in the direction connecting the one end and the other end of the blood collection container main body.

1,1A, 1B, 1C, 1D, 1E, 1F ... Serine proteases 1a, 1Aa, 1Ba, 1Ca, 1Da, 1Ea, 1Fa, 1b, 1Ab, 1Bb, 1Cb, 1Db, 1Eb, 1Fb ...

End

2,2A, 2B, 2C, 2D, 2E, 2F ... Heparin neutralizer 2a, 2Aa, 2Ba, 2Ca, 2Da, 2Ea, 2Fa, 2b, 2Ab, 2Bb, 2Cb, 2Db, 2Eb, 2Fb ...

Ends

3,3A, 3C, 3D, 3E, 3F ... Inorganic powder 3a, 3Aa, 3Ca, 3Da, 3Ea, 3Fa, 3b, 3Ab, 3Cb, 3Db, 3Eb, 3Fb ... End 4 ... Blood collection container body 4a ... One end 4b ... End 5 ... Serum Separation composition 6 ...

Plugs

11, 11A, 11B, 11C, 11D, 11E, 11F ... Blood collection vessel R1 ... First region R2 ... Second region R3 ... Third region R12, R13, R23 ... Overlapping region

Claims

A blood collection container body having an opening at one end and a closed bottom at the other end,
The serine protease placed in the blood collection container body and
A heparin neutralizer arranged in the blood collection container body is provided.
When the region where the serine protease is arranged is defined as the first region and the region where the heparin neutralizer is arranged is defined as the second region,
A blood collection container having a region in which the second region exists on the other end side of the first region on the other end side.
There is or does not have an overlapping region where the first region and the second region overlap.
When there is an overlapping region where the first region and the second region overlap, the first region with respect to the distance between the end portion on the one end side and the end portion on the other end side of the second region. The blood sampling according to claim 1, wherein the ratio of the distance between the end on one end side and the end on the other end side of the overlapping region where the region of 1 and the second region overlap is 0.2 or less. container.
The inorganic powder arranged in the blood collection container body is provided.
When the region where the inorganic powder is arranged is set as the third region,
The blood collection container according to claim 1 or 2, wherein the third region has a region existing on the other end side of the other end side of the first region.
The blood collection container according to claim 3, wherein the third region has a region existing on one end side of the one end side of the second region.
The blood collection container according to claim 3 or 4, wherein the second region has a region existing on the other end side of the other end side of the third region.
The blood collection container according to any one of claims 3 to 5, wherein the inorganic powder is silica powder.
The blood collection vessel according to any one of claims 1 to 6, wherein the serine protease is thrombin, a thrombin-like enzyme, or a fibrinogen-degrading enzyme.
The blood collection container according to any one of claims 1 to 7, further comprising an antifoaming agent arranged at least at the bottom of the blood collection container body.
The blood collection container according to any one of claims 1 to 8, further comprising a serum separation composition contained in the bottom of the blood collection container body.